Skip to main content
SpringerLink
Log in

High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer

  • Chapter
  • First Online:
Book cover Inflammatory Breast Cancer: An Update

  • 789 Accesses

Abstract

Inflammatory breast cancer (IBC) is a rare type of invasive breast cancer with only about 5% of all breast cancer cases. However, it is one of the most aggressive forms of invasive breast cancer. It frequently presents with regional lymph node involvement at presentation and is followed by rapid disease progression to distant involvement from micrometastasis in the natural course of disease. With locoregional treatment only, long-term survival is less than 5% [1]. With the addition of systemic cytotoxic chemotherapy together with locoregional treatment, the long term survival has improved significantly but still at the range of 30–50% [2]. Inflammatory breast cancer being a systemic disease and also a chemo-sensitive disease, it makes sense that systemic cytotoxic therapy is the main force of treatment. The main issue is how to improve the systemic treatment to achieve a better survival outcome. One way to improve the systemic treatment is through the concept of dose intensity of cytotoxic chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ueno NT, Buzdar AU, Singletary SE et al (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40:321–329

    Article  PubMed  CAS  Google Scholar 

  2. Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10:1014–1024

    PubMed  CAS  Google Scholar 

  3. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281–1288

    PubMed  CAS  Google Scholar 

  4. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162–1170

    PubMed  CAS  Google Scholar 

  5. Hryniuk WM, Levine MN, Levin L (1986) Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986 (1):87–94

    Google Scholar 

  6. Wilking N, Lidbrink E, Wiklund T et al (2007) Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18:694–700

    Article  PubMed  CAS  Google Scholar 

  7. Hanrahan EO, Broglio K, Frye D et al (2006) Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106:2327–2336

    Article  PubMed  CAS  Google Scholar 

  8. Roché HH, Pouillart P, Meyer N et al (2001) Adjuvant high-dose chemotherapy (HDC) improves early outcome for high risk (N  >  7) breast cancer patients: the PEGASE 01 trial. Proc Am Soc Clin Oncol 20 :abstr 102

    Google Scholar 

  9. Gianni A, Bonadonna G (2007) Updated 12-year results of a randomized clinical trial comparing standard-dose versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than 3 positive nodes (LN+). Proc Am Soc Clin Oncol 25 :abstr 549

    Google Scholar 

  10. Schrama JG, Faneyte IF, Schornagel JH et al (2002) Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 13:689–698

    Article  PubMed  CAS  Google Scholar 

  11. Rodenhuis S, Bontenbal M, Beex LV et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7–16

    Article  PubMed  CAS  Google Scholar 

  12. Tallman MS, Gray R, Robert NJ et al (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349:17–26

    Article  PubMed  CAS  Google Scholar 

  13. Leonard RC, Lind M, Twelves C et al (2004) Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 96:1076–1083

    Article  PubMed  CAS  Google Scholar 

  14. Zander AR, Schmoor C, Kroger N et al (2008) Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 19:1082–1089

    Article  PubMed  CAS  Google Scholar 

  15. Coombes RC, Howell A, Emson M et al (2005) High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 16:726–734

    Article  PubMed  CAS  Google Scholar 

  16. Nitz UA, Mohrmann S, Fischer J et al (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366:1935–1944

    Article  PubMed  CAS  Google Scholar 

  17. Peters WP, Rosner GL, Vredenburgh JJ et al (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23:2191–2200

    Article  PubMed  Google Scholar 

  18. Basser RL, O’Neill A, Martinelli G et al (2006) Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15–95. J Clin Oncol 24:370–378

    Article  PubMed  Google Scholar 

  19. Moore HC, Green SJ, Gralow JR et al (2007) Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 25:1677–1682

    Article  PubMed  CAS  Google Scholar 

  20. Tokuda Y, Tajima T, Narabayashi M et al (2008) Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 99:145–151

    PubMed  CAS  Google Scholar 

  21. Berry D, Ueno N, Johnson MM et al (2011) High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 29:3214–3223

    Google Scholar 

  22. Stadtmauer EA, O’Neill A, Goldstein LJ et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069–1076

    Article  PubMed  CAS  Google Scholar 

  23. Stadtmauer EA, O’Neill A, Goldstein LJ et al (2002) Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (SCT) for metastatic breast cancer: 5-year update of the ‘Philadelphia Trial’ (PBT-01). Proc Am Soc Clin Oncol 21 :abstr 169

    Google Scholar 

  24. Crown J, Perey L, Lind M et al (2003) Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): the International Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol 22 :abstr 88

    Google Scholar 

  25. Schmid P, Schippinger W, Nitsch T et al (2005) Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 23:432–440

    Article  PubMed  CAS  Google Scholar 

  26. Lotz JP, Cure H, Janvier M et al (2005) High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 41:71–80

    Article  PubMed  CAS  Google Scholar 

  27. Vredenburgh JJ, Coniglio D, Broadwater G et al (2006) Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 12:195–203

    Article  PubMed  CAS  Google Scholar 

  28. Vredenburgh JJ, Madan B, Coniglio D et al (2006) A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 37:1009–1015

    Article  PubMed  CAS  Google Scholar 

  29. Biron P, Durand M, Roche H et al (2008) Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 41:555–562

    Article  PubMed  CAS  Google Scholar 

  30. Crump M, Gluck S, Tu D et al (2008) Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 26:37–43

    Article  PubMed  CAS  Google Scholar 

  31. Berry D, Ueno N, Johnson MM et al (2011) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of 6 randomized trials. J Clin Oncol 29:3224–3231

    Google Scholar 

  32. Antman KH, Rowlings PA, Vaughan WP et al (1997) High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870–1879

    PubMed  CAS  Google Scholar 

  33. Pedrazzoli P, Ferrante P, Kulekci A et al (2003) Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) registry 1990–1999. Bone Marrow Transplant 32:489–494

    Article  PubMed  CAS  Google Scholar 

  34. Ayash LJ, Elias A, Ibrahim J et al (1998) High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 16:1000–1007

    PubMed  CAS  Google Scholar 

  35. Somlo G, Doroshow JH, Forman SJ et al (1997) High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 15:2882–2893

    PubMed  CAS  Google Scholar 

  36. Cheng YC, Rondon G, Yang Y et al (2004) The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant 10:794–804

    Article  PubMed  CAS  Google Scholar 

  37. Viens P, Palangie T, Janvier M et al (1999) First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81:449–456

    Article  PubMed  CAS  Google Scholar 

  38. Viens P, Penault-Llorca F, Jacquemier J et al (1998) High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 21:249–254

    Article  PubMed  CAS  Google Scholar 

  39. Dazzi C, Cariello A, Rosti G et al (2001) Neoadjuvant high dose chemotherapy plus peripheral blood progenitor cells in inflammatory breast cancer: a multicenter phase II pilot study. Haematologica 86:523–529

    PubMed  CAS  Google Scholar 

  40. Palangie T, Pouillart P, Roche H et al (2006) Five year update of sequential high dose doxorubicin, cyclophosphamide and docetaxel in inflammatory breast cancer; PEGASE05 trial on behalf of FNLCC. Proc Am Soc Clin Oncol 24 :abstr 10773

    Google Scholar 

  41. Cagnoni PJ, Nieto Y, Shpall EJ et al (1998) High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 16:1661–1668

    PubMed  CAS  Google Scholar 

  42. Schwartzberg L, Weaver C, Lewkow L et al (1999) High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant 24:981–987

    Article  PubMed  CAS  Google Scholar 

  43. Adkins D, Brown R, Trinkaus K et al (1999) Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol 17:2006–2014

    PubMed  CAS  Google Scholar 

  44. Arun B, Slack R, Gehan E et al (1999) Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer 85:93–99

    Article  PubMed  CAS  Google Scholar 

  45. Yalamanchili K, Lalmuanpuii J, Waheed F et al (2008) High-dose chemotherapy with autologous stem cell rescue in stage IIIB inflammatory breast cancer. Anticancer Res 28:3139–3142

    PubMed  CAS  Google Scholar 

  46. Sportes C, Steinberg SM, Liewehr DJ et al (2009) Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. Biol Blood Marrow Transplant 15:963–970

    Article  PubMed  CAS  Google Scholar 

  47. Roche H, Viens P, Biron P et al (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10:42–47

    PubMed  Google Scholar 

  48. Viens P, Tarpin C, Roche H et al (2010) Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience. Cancer 116:2829–2836

    Article  PubMed  CAS  Google Scholar 

  49. Cheng YC, Ueno NT (2010) Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal? Womens Health (Lond Engl) 6:481–485

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

    Yee Chung Cheng M.D.

  2. Morgan Welch Inflammatory Breast Cancer Program and Clinic, Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Unit 1354, Holcombe Blvd. 1515, Houston, TX, USA

    Naoto T. Ueno M.D., Ph.D., F.A.C.P.

Authors
  1. Yee Chung Cheng M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoto T. Ueno M.D., Ph.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yee Chung Cheng M.D. .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Dept. Breast Medical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030-4095, Texas, USA

    Naoto T. Ueno

  2. Fox Chase Cancer Center, Cottman Avenue; Room C315 333, Philadelphia, 19111, Pennsylvania, USA

    Massimo Cristofanilli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Cheng, Y.C., Ueno, N.T. (2012). High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer. In: Ueno, N., Cristofanilli, M. (eds) Inflammatory Breast Cancer: An Update. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-3907-9_12

Download citation

Publish with us

Policies and ethics

Search

Navigation